New treatment for PE on the horizon: Biovail BVF-324
Canadian pharmaceutical company Biovail licensed a drug from an undisclosed Biotech firm in 2007. The drug (BVF-324) is a treatement for premature ejaculation. Most probably BVF-324 has the same mechanism as many anti-depressants and is in Phase III of clinical trials.
Leave a Reply